Journal Article (Letter)

DKFZ-2026-01833

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.

Jovein, M. M. ; Meyer, T. ; Waterhouse, M. ; Pfeifer, D. ; Duque-Afonso, J. ; Maas-Bauer, K. ; Duyster, J. ; Wäsch, R. ; Finke, J. ; Zeiser, R.DKFZ* ; Wehr, C.

2026
Elsevier B. V. [Amsterdam]

Keyword(s): GvHD prophylaxis ; allogeneic stem cell transplantation ; graft-versus-host disease ; myelofibrosis ; ruxolitinib

Note: #DKTKZFB26# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Freiburg (FR01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---